Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
about
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Improving oncologic outcomes for women with endometrial cancer: realigning our sightsDevelopment of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancerAn analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.Management of women with surgically staged 1 uterine papillary serous cancer.High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinomaRedefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progressionEndometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.Trends in the demographic and clinicopathological characteristics in Japanese patients with endometrial cancer, 1990-2010.Brain metastasis in two patients with stage IA papillary serous carcinoma of the uterus.The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone.An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review).A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.Uterine papillary serous carcinoma: a review.A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system.Personalized care in uterine cancer.Endometrial serous carcinoma: its molecular characteristics and histology-specific treatment strategies.Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer.Molecular target therapies in endometrial cancer: from the basic research to the clinic.Pharmacotherapy of endometrial cancer.Taxanes: their impact on gynecologic malignancy.Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Clinicopathologic study in uterine cancer.No cookie-cutter oncology: individualized treatment approaches for women with corpus endometrial cancer.Unresolved issues in the management of endometrial cancer.Clinical management of uterine papillary serous carcinoma.Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.Evaluation of adjuvant therapy in women with uterine papillary serous cancer.Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report.Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.Prognostic impact of lymphadenectomy in uterine serous cancer.[Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].Clinical Behavior and Treatment of Endometrial Cancer.
P2860
Q33633962-7344D68A-CE13-4B96-8C23-3747D17B4456Q33926124-5CDED03E-78EA-49F7-B625-E1227071D159Q34634149-F11E3FEF-3ABB-4117-9B9D-AA915A42C4BCQ34996963-3D0362DB-100E-4135-9159-D389E082B698Q35174196-243369FE-ADAA-4D71-B819-E6D8F2FC2C15Q35207926-76D0E0EF-FFFA-40E1-B92B-A88249A6D8F6Q35210293-93BA6023-D4E7-4A80-B55F-853D49B25741Q35517957-1AC2DC14-D8ED-47B1-AB14-865B9FDA5813Q35609272-F1A14F1C-8C6E-4F95-9442-6120A7406BFCQ36003197-C4758496-61FF-4462-9FD0-A6217511DF7BQ36008845-B4C82F36-40FC-4EAD-BA35-36AEEB055A87Q36039847-44A3B7E0-7D13-41DA-91A0-819EA23B32D4Q36475131-36DA74D7-28AF-4FFC-91CA-F122CF27D093Q36600227-EFAB8FB7-7E61-4CCE-88C6-EDA1ADDEAFFDQ36684551-725BE366-977C-4E50-B054-5646D6CF13F1Q36737086-8F19C02B-BA81-46E4-968F-E1372F028760Q36787306-D12E03EC-851B-47E9-85F8-B7CEBAA02582Q36817475-CB2F6D98-BE8F-4D87-B6C7-DACDDD36C7E2Q37006856-4CF983D6-4059-4F95-B142-685F707E6BEAQ37017041-2147120F-66F6-40AE-BCDF-C41F4B07BA0AQ37148408-B1B2D192-335A-4FD0-BD55-AC8531A113E6Q37196543-4E84BBFA-8C89-48B5-AC26-510548921222Q37544822-D1016DE3-46AB-448B-B11A-690D235A8EECQ37692801-31A5448D-9F36-4108-9951-6D013AF62305Q37699264-2A5BCCD1-EA4B-47D1-92E1-1E0294757CFDQ37709899-BB50B864-CDB8-4E3A-B35F-9D806605A27DQ37774355-A991D4F7-DF35-48CF-9CF1-58E479CAE6AEQ37821897-8F568BF4-FE85-42D7-B8F1-E808881D5FC2Q37821898-B468E155-7FB2-4C22-8A01-9E414D5A0AFAQ38297206-1C19D4BC-9F54-4D89-AB3F-27FDCE3172B7Q38380255-CA2E8423-C814-4C22-B087-3323507FA989Q39677120-892F4757-591B-4808-86A5-F4225EAB40D4Q39811675-0B8C1301-6E29-4561-9529-9BB93394D3E9Q41721420-CD89B67F-1946-4A12-9198-85196559C51FQ41970635-A7BEE0AA-BCBA-43E5-A310-18448C2164AEQ44953646-6E716AA7-30F3-46FB-A586-7DA6ED56386BQ46078660-FE742C37-DA21-46C2-ACCB-5483B6C6CDA8Q47347535-33EFA53B-D5F4-4C93-95B5-875023043807Q52981800-B43D116F-FC8C-4CAD-9A9C-BB700577E099Q54011680-DC7FC47B-B6A3-452D-9031-96180A7B64B6
P2860
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Improved survival in surgical ...... t platinum-based chemotherapy.
@ast
Improved survival in surgical ...... t platinum-based chemotherapy.
@en
Improved survival in surgical stage I patients with uterine papillary serous carcinoma
@nl
type
label
Improved survival in surgical ...... t platinum-based chemotherapy.
@ast
Improved survival in surgical ...... t platinum-based chemotherapy.
@en
Improved survival in surgical stage I patients with uterine papillary serous carcinoma
@nl
prefLabel
Improved survival in surgical ...... t platinum-based chemotherapy.
@ast
Improved survival in surgical ...... t platinum-based chemotherapy.
@en
Improved survival in surgical stage I patients with uterine papillary serous carcinoma
@nl
P2093
P1433
P1476
Improved survival in surgical ...... t platinum-based chemotherapy.
@en
P2093
David M O'malley
Herbert Yu
Jessica McAlpine
Masoud Azodi
Michael G Kelly
Peter E Schwartz
Thomas J Rutherford
P304
P356
10.1016/J.YGYNO.2005.06.012
P407
P577
2005-09-01T00:00:00Z